The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
about
The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladderClinical use of the β3 adrenoceptor agonist mirabegron in patients with overactive bladder syndromeMirabegron: a Beta-3 agonist for overactive bladder.An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Sirolimus and mirabegron interaction in a hematopoietic cell transplant patient.
P2860
The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
The effect of mirabegron, a po ...... es desipramine and metoprolol.
@en
The effect of mirabegron, a po ...... es desipramine and metoprolol.
@nl
type
label
The effect of mirabegron, a po ...... es desipramine and metoprolol.
@en
The effect of mirabegron, a po ...... es desipramine and metoprolol.
@nl
prefLabel
The effect of mirabegron, a po ...... es desipramine and metoprolol.
@en
The effect of mirabegron, a po ...... es desipramine and metoprolol.
@nl
P2093
P2860
P1476
The effect of mirabegron, a po ...... es desipramine and metoprolol.
@en
P2093
Gregory Strabach
James Dickinson
Jeroen van de Wetering
John Meijer
Marcel van Gelderen
Marloes Schaddelee
Reiner Tretter
Walter Krauwinkel
P2860
P2888
P356
10.1007/S13318-013-0133-1
P577
2013-06-01T00:00:00Z